Parvovirus B19 and the new century

Clinical Infectious Diseases

Volumn 46, Issue 4, 2008, Pages 537-539

  Bassols, Angel C ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PLACEBO; RECOMBINANT PARVOVIRUS B19 VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS VACCINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; BLOOD SAMPLING; BONE MARROW; CLINICAL TRIAL; CYTOPENIA; DISEASE ASSOCIATION; DISEASE SEVERITY; ERYTHEMA INFECTIOSUM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LEUKEMIA RELAPSE; MALARIA; NOTE; PANCYTOPENIA; PARVOVIRUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SICKLE CELL ANEMIA; UNITED STATES; CHILD; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOLOGY; VIROLOGY; VIRUS INFECTION;

CHILD; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 38849088183     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/526523     Document Type: Note

References (32)

1. Lindblom A, Heyman M, Gustafsson I, et al. Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy. Clin Infect Dis 2008; 46:528-36 (in this issue).
2. Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med 2006; 260:285-304.
3. Young NS, Brown KE. Parvovirus B19. NEngl J Med 2004; 350:586-97.
4. Reed J, Brown K, Young N. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay. J Infect Dis 1999; 179:619-26.
5. Norbeck O, Isa A, Pöhlmann C, et al. Sustained CD8 T-cell responses induced after acute parvovirus B19 infection in humans. J Virol 2005; 79:12117-21.
6. Lindblom A, Isa A, Norbeck O, et al. Slow clearance of human parvovirus B19 viremia following acute infection. Clin Infect Dis 2005; 41:1201.
7. Heegaard ED, Schmiegelow. Serologic study on parvovirus B19 infection in childhood acute lymphoblastic leukemia during chemotherapy: clinical and hematologic implications. J Pediatr Hematol Oncol 2002; 24:368-73.
8. Kuo SH, Lin LI , Chang CJ, et al. Increased risk of parvovirus B19 infection in young adult cancer patients receiving multiple courses of chemotherapy. J Clin Microbiol 2002; 40:3909-12.
9. El-Mahallawy HA, Mansour T, El-Din SE, Hafez M, Abd-el-Latif S. Parvovirus B19 infection as a cause of anemia in pediatric acute lymphoblastic leukaemia during maintenance chemotherapy. J Pediatr Hematol Oncol 2004; 26:403-6.
10. Kerr JR, Barah F, Cunniffe VS, et al. Association of acute parvovirus B19 infection with new onset of acute lymphoblastic and myeloblastic leukemia. J Clin Pathol 2003; 56:873-5.
11. Heegaard ED, Jensen L, Hornsleth A, Schmiegelow K. The role of parvovirus B19 infection in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1999; 16:329-34.
12. Rising incidence of parvovirus B19 infection. Commun Dis Rep CDR Wkly 1998; 8:93, 96.
13. Nguyen QT, Sifer C, Schneider V, et al. Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 1999; 37:2483-7.
14. Manning A, Willey SJ, Bell JE, Simmonds P. Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PAR4 and human bocavirus. J Infect Dis 2007; 195:1345-52.
15. Brown KE. Haematological conseques of parvovirus B19 infection. Baillieres Best Pract Res Clin Haematol 2000; 13:245-59.
16. Mustafa MM, McClain KL. Diverse hematologic effects of parvovirus B19 infection. Pediatr Clin North Am 1996; 43:809-21.
17. Shah SM, Graeber C. Acute renal failure following intravenous immunoglobulin therapy. Hospital Physician 2005; 29-32. Available at: http://www.turner-white.com. Accessed November 2007.
18. Chapman SA, Gilkerson KL, Davin TD, Pritzker MR. Acute renal failure and intravenous immune globuline: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother 2004; 38:2059-67.
19. Itkin YM, Trujillo TC. Intravenous immunoglobulin-associated acute renal failure: case series and literature review. Pharmacotherapy 2005; 25:886-92.
20. Vo AA, Cam V, Toyoda M, et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin JAm Soc Nephrol 2006; 1:844-52.
21. Bansal GP, Hatfield JA, Dunn FE, et al. Candidate recombinant vaccine for human B19 parvovirus. Infect Dis 1993; 5:1034-44.
22. Tsao EI, Mason MR, Cacciuttolo MA, et al. P of parvovirus B19 vaccine in insect cells coinfected with double baculoviruses. Biotechnol Bioengineer 2000; 49:130-8.
23. MF59c.1-adjuvanted recombinant vaccine reported safe, immunogenic. Vaccine Wkly 2003. Available at: http://www.newsrx.com/article.php? articleIDp135276. Accessed November 2007.
24. Ballou R, Reed J, Noble W, Young N, Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003; 187:675-8.
25. ClinicalTrials.gov. B-19 parvovirus vaccine study by clinical trials. Available at: http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00379938. Accessed October 2007.
26. Lunardi C, Tiso M, Borgato L, et al. Chronic parvovirus B19 infection induces the poduction of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 1998; 28:936-48.
27. La Monte AC, Mary E, Paul ME, et al. Persistent parvovirus B19 infection without the development of chronic anemia in HIV-infected and -uninfected children: the Woman and Infants Transmission Study. J Infect Dis 2004; 189:847-51.
28. Wildig J, Michon P, Siba P, et al. Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea. J Infect Dis 2006; 194:146-53.
29. World Health Organization. World malaria report 2005. Geneva, Switzerland: World Health Organization, 2006.
30. Shenoy S. Has steam cell transplantation come of age in the treatment of sickle cell disease? Bone Marrow Transplant 2007; 40:813-21.
31. Waldman M, Kopp JB. Parvovirus B19 and the kidney. Clin J Am Soc Nephrol 2007; 2(Suppl 1):S47-56.
32. Frickhofen N, Abkowitz J, Safford M, et al. Persistent parvovirus infection in patients infected with human immunodeficiency virus type 1: a treatable cause of anemia in AIDS. Ann Intern Med 1990; 113:926-33.